CD273抗体;CD273 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CD273 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD273 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of K562 cells using CD273 mouse mAb (green) and negative control (red).    

  
  

CD273 (also known as PD-L2 or programmed death-ligand 2) is a transmembrane protein belonging to the B7 family of immune checkpoint molecules. It binds to the PD-1 receptor on T cells, delivering co-inhibitory signals to suppress T-cell activation and promote immune tolerance. CD273 is primarily expressed on antigen-presenting cells (e.g., dendritic cells, macrophages) and certain tumor cells. Its interaction with PD-1 helps maintain peripheral tolerance but can also be exploited by cancers to evade immune surveillance.

CD273 antibodies are therapeutic or research tools targeting this pathway. Antagonistic antibodies blocking CD273/PD-1 aim to restore anti-tumor immunity, potentially enhancing cancer immunotherapy. Conversely, agonistic antibodies may dampen excessive immune responses in autoimmune diseases. Structurally, CD273 shares homology with PD-L1 (CD274), another PD-1 ligand, but differs in expression patterns and binding affinity. While PD-L1 is broadly upregulated in tumors, CD273 expression is more restricted, suggesting context-dependent roles.

Research on CD273 antibodies explores their efficacy alone or combined with PD-1/PD-L1 inhibitors. Preclinical studies highlight their potential in modulating T-cell exhaustion and improving checkpoint blockade therapy. However, clinical development remains less advanced compared to PD-1/PD-L1-targeted agents, underscoring the need for further mechanistic and translational studies.